(Q38063585)

28 August 2017

1 reference

title

Anti-TNF-α biotherapies: perspectives for evidence-based personalized medicine (English)

1 reference

28 August 2017

0 references

0 references

personalized medicine

1 reference

Klaus Bendtzen

1

1 reference

28 August 2017

publication date

1 November 2012

1 reference

28 August 2017

1 reference

28 August 2017

volume

4

1 reference

28 August 2017

issue

11

1 reference

28 August 2017

page(s)

1167-1179

1 reference

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010.

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.114

Immunohistological detection of interleukin I-like molecules and tumour necrosis factor in human epidermis before and after UVB-irradiation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.114

Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis. Implications for local actions of tumor necrosis factor alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.114

Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.114

Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.114

Mouse/human chimeric monoclonal antibody in man: kinetics and immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.114

Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.114

Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.114

Optimizing anti-tumor necrosis factor strategies in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.114

Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.114

Patient outcomes after anti TNF-alpha drugs for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.114

Biologic therapies in rheumatology: lessons learned, future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.114

Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.114

The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.114

The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expression in the synovium

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.114

Optimizing outcomes in patients with rheumatoid arthritis and an inadequate response to anti-TNF treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.114

Antibodies against erythropoietin and other protein-based therapeutics: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.114

Scientific and regulatory considerations on the immunogenicity of biologics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.114

Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.114

Clinical concerns of immunogenicity produced at cellular levels by biopharmaceuticals following their parenteral administration into human body

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.114

Immunoregulation by naturally occurring and disease-associated autoantibodies : binding to cytokines and their role in regulation of T-cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.114

Immunogenicity of biological agents in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.114

Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.114

Non-response to infliximab may be due to innate neutralizing anti-tumour necrosis factor-alpha antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.114

Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.114

Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.114

Dealing with immunogenicity of biologicals: assessment and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.114

Immunogenicity of Anti-TNF-alpha agents in autoimmune diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.114

Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.114

Etanercept and venous thromboembolism: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.114

Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.114

Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.114

Assessing response and loss of response to biological therapies in IBD.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.114

Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.114

Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.114

Bronchospasm associated with anti-TNF treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.114

Rationally engineered therapeutic proteins with reduced immunogenicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.114

Immunogenicity of engineered antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.114

Immunogenicity of protein therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.114

Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.114

Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.114

Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.114

Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.114

Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.114

21 January 2018

Identifiers

DOI

10.2217/IMT.12.114

1 reference

28 August 2017

1 reference